HGEN - Humanigen gains as it enters pact with PCI Pharma Services in UK for lenzilumab

Humanigen (NASDAQ:HGEN) is up 2.2% premarket after the firm has entered into an agreement with PCI Pharma Services, a leading integrated global contract development manufacturing organization (CDMO), to provide importation, release and commercialization services in the United Kingdom for lenzilumab. Per the terms, PCI will purchase lenzilumab for resale and distribution in the event a Conditional Marketing Authorization is received in the UK for use in patients hospitalized with COVID-19. Lenzilumab is an investigational product and is not approved or authorized in any country. The company is currently advancing its experimental COVID-19 therapy lenzilumab in a Phase 2/3 trial conducted by the National Institutes of Health (NIH). Its topline data are expected in late Q1 or early Q2.

For further details see:

Humanigen gains as it enters pact with PCI Pharma Services in UK for lenzilumab